<DOC>
	<DOCNO>NCT01478113</DOCNO>
	<brief_summary>This study aim identify novel enhancement strategy residual symptom major depressive disorder ( MDD ) Dopamine ( DA ) view `` pleasure neurotransmitter '' 30 year . Yet recent data animal human study suggest dopamine great effect `` want '' `` liking . '' Therefore , investigator study hypothesize amphetamine/d-amphetamine ( AMPH ) , medication increase dopamine transmission reward center brain , may powerful antidepressant effect combination well-being therapy ( WBT ) , specific type cognitive-behavioral therapy , help individual depression increase contact natural reward decrease reward-interfering thought . The investigator test hypothesis randomize 40 individual residual symptom depression , already take antidepressant affect serotonin ( e.g . Prozac , Paxil ) , 8 week treatment either WBT combination AMPH , WBT pill placebo . The effectiveness treatment measure use reliable scale , call Hamilton Depression Rating Scale . The investigator also hypothesize people assigned stimulant/WBT group great improvement function , well-being , positive affectivity people assign WBT/placebo group .</brief_summary>
	<brief_title>Stimulant Enhancement Well-Being Therapy Depression</brief_title>
	<detailed_description>The study 11 visit occur 8 week study visit schedule weekly biweekly . Detailed Description : The study visit occurrence follow : 1 . Week 0- Screening Visit 2 . Week 1- Baseline Visit 3 . Week 2- one phone visit one clinic visit one week 4 . Week 3- one phone visit one clinic visit one week 5 . Week 4- one visit one week 6 . Week 5- one visit one week 7 . Week 6- one visit one week 8 . Week 7- one visit one week 9 . Week 8- one visit one week WBT description Four license therapist , train certified WBT , provide weekly session 30 50 minute duration . Therapists follow procedure outline WBT manual . The initial session ( week 0-2 ) focus identify contextualizing episodes well-being . The intermediate session ( week 3-5 ) focus modify cognition behavior , lead premature interruption well-being , optimize cognition behavior , idiographically link enhanced well-being . Final session ( week 6-8 ) apply Psychological Well-Being scale ( PWB ) refine treatment accord Ryff 's dimension well-being . Additional principle technique WBT include reappraisal , mood-charting , schedule activity , shape , problem-solving , assertiveness training . Medication Schedule Participants receive treatment stimulant , amphetamine/d-amphetamine , matched placebo . Participants start 1 pill ( placebo 5 mg amphetamine/d-amphetamine ) morning 1 pill ( placebo 5 mg amphetamine/d-amphetamine ) noon . The treatment flexibly adjust study clinician base participant 's response . Dose range 1-3 pill ( placebo 5 mg amphetamine ) morning 1-3 pill ( placebo 5 mg amphetamine ) noon .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Inclusion Criteria 1 . Outpatients 18 60 year age . 2 . Experiencing residual symptom 8 week SSRI therapy , least 4 week stable dose current agent prior randomization . 3 . Fulfillment DSMIV diagnostic criterion MDD present episode illness continue residual symptom . 4 . A score 14 26 31item Hamilton Depression Rating Scale ( HAMD31 ) screen randomization . 5 . A Clinical Global Impression Severity ( CGIS ) score 3 4 screening randomization . Exclusion Criteria 1 . Treatment within 4 week randomization nonSSRI antidepressant , antipsychotic , mood stabilizer , stand benzodiazepine , stimulant , stimulantlike agent . 1 . Allowed exception 1 : Concomitant benzodiazepine , stable dose , take least one year history abuse . 2 . Allowed exception 2 : Effexor , duloxetine ( Cymbalta ) milnacipran ( Savella ) serve main SSRI treatment . 3 . Allowed exception 3 : Combinations SSRIs ( ex . Zoloft &amp; Lexapro concomitantly ) acceptable main SSRI treatment . 2 . If subject endorse `` yes '' `` agree '' item 12 23 CHRT , would indicate active suicidality would exclusionary . 3 . Significant suicide risk . 4 . Current treatmentresistant episode MDD . 5 . A primary diagnosis Axis I disorder MDD . 6 . History psychotic disorder , dysthymia , antisocial personality disorder , BPD , mental retardation . 7 . History substance use disorder , exception nicotine dependence , within 12 month prior screen . 8 . History stimulant abuse , prescription drug abuse , eat disorder . 9 . Initial insomnia screen adequately control medication . Subjects recent history unstable insomnia define active poorly control symptom insomnia within past 1 month exclude . 10 . Comorbid medical condition include structural heart defect rhythm abnormality might exacerbate stimulant therapy ; hypertension measure rest sit systolic blood pressure &gt; 149mmHg diastolic blood pressure &gt; 95mmHg ; tachycardia measure sit pulse rate &gt; 100 bpm &lt; 50 bpm rest 5 minute . 11 . Allergy , hypersensitivity , intolerance , history nonresponsivity stimulant medication . 12 . History nonresponsivity CBT wellbeing therapy . 13 . Women pregnant breastfeeding . 14 . Glaucoma hyperthyroidism 15 . Current concomitant therapy permit supportive therapy ( specifically CBT ) ongoing least one year . However , subject therapy less one year wish discontinue take hiatus current therapy come screen visit , allow . Additionally , subject may enter talk therapy duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Therapy</keyword>
	<keyword>Medication study</keyword>
	<keyword>Depression</keyword>
	<keyword>Therapy study</keyword>
</DOC>